Kathryn Romano Sells 750 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) CAO Kathryn Romano sold 750 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Krystal Biotech Price Performance

Shares of KRYS stock traded up $3.52 on Tuesday, hitting $175.35. 169,344 shares of the stock traded hands, compared to its average volume of 262,634. The firm has a market cap of $5.05 billion, a price-to-earnings ratio of 58.58 and a beta of 0.87. The firm has a 50 day simple moving average of $159.63 and a two-hundred day simple moving average of $174.93. Krystal Biotech, Inc. has a 52 week low of $141.72 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analysts' expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business's quarterly revenue was up 116.4% on a year-over-year basis. During the same period last year, the firm earned $0.30 earnings per share. Sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Remove Ads

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently added to or reduced their stakes in KRYS. Creative Planning lifted its stake in Krystal Biotech by 64.9% in the third quarter. Creative Planning now owns 5,744 shares of the company's stock worth $1,046,000 after purchasing an additional 2,260 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Krystal Biotech by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,039 shares of the company's stock valued at $184,000 after acquiring an additional 186 shares during the period. New York State Teachers Retirement System boosted its holdings in Krystal Biotech by 6.6% during the 3rd quarter. New York State Teachers Retirement System now owns 15,879 shares of the company's stock valued at $2,890,000 after acquiring an additional 979 shares during the period. First Trust Direct Indexing L.P. bought a new position in Krystal Biotech in the 3rd quarter valued at $252,000. Finally, Janney Montgomery Scott LLC increased its stake in Krystal Biotech by 17.1% in the third quarter. Janney Montgomery Scott LLC now owns 37,047 shares of the company's stock worth $6,744,000 after purchasing an additional 5,415 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on KRYS shares. Chardan Capital increased their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. HC Wainwright reiterated a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Friday. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Krystal Biotech has an average rating of "Buy" and a consensus target price of $215.83.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).